Biography:Scott Shields Emerson
From HandWiki
Scott Shields Emerson is an American biostatistician and emeritus professor of the University of Washington.[1][2]
Emerson was a professor of biostatistics[3] at the University of Washington in the School of Public Health's department of biostatistics[4] from 1999[5] to 2017.[6][7] Emerson worked on randomized controlled trial design.[8][9] Emerson has been part of advisory committees for the Food and Drug Administration,[10][11] including on work related to Aduhelm.[12][13]
Schooling
Emerson studied at the University of Virginia and the University of Washington.
References
- ↑ Joseph, Andrew (June 8, 2021). "Member of FDA's expert panel resigns over controversial Alzheimer's therapy approval". https://www.statnews.com/2021/06/08/fda-expert-panel-resigns-alzheimers-approval/.
- ↑ "Aducanumab Data Finally Published, but Alzheimer's Experts Spot Problems". March 23, 2022. https://www.medpagetoday.com/neurology/alzheimersdisease/97839.
- ↑ "FDA Committee Expresses Concerns about Promising Alzheimer's Drug". Time. https://time.com/5908589/alzheimers-drug-biogen-fda-committee/.
- ↑ "Emerson Statistics | R information". http://www.uwintrostats.org/index.asp.
- ↑ Scott Shields Emerson. "Curriculum Vitae". http://www.emersonstatistics.com/dnlds/semerson.pdf.
- ↑ "Scott S. Emerson, M.D., Ph.D. | Home Page". https://faculty.washington.edu/semerson/.
- ↑ "| UW School of Public Health". https://sph.washington.edu/faculty/facbio/Emerson_Scott.
- ↑ Emerson, Scott S.; Kittelson, John M.; Gillen, Daniel L. (December 10, 2007). "Frequentist evaluation of group sequential clinical trial designs". Statistics in Medicine 26 (28): 5047–5080. doi:10.1002/sim.2901. PMID 17573678.
- ↑ "RCTdesign.org : Methods and Software for Clinical Trials". http://rctdesign.org/Welcome.html.
- ↑ "Advisory Committee Again Urges FDA to Vote No on Aducanumab | ALZFORUM". https://www.alzforum.org/news/community-news/advisory-committee-again-urges-fda-vote-no-aducanumab.
- ↑ Herman, Bob (July 27, 2021). "Biogen pulled Aduhelm paper after JAMA demanded edits". https://www.axios.com/2021/07/27/biogen-jama-aduhelm-clinical-trial-results-publish.
- ↑ "JAMA Paper Withdrawal Adds One More Layer to Aduhelm Controversy". https://www.biospace.com/article/biogen-withdraws-aduhelm-clinical-trial-paper-from-jama/.
- ↑ Review, The Regulatory (July 6, 2021). "Regulatory Reactivity in FDA's Approval of Aduhelm | The Regulatory Review". https://www.theregreview.org/2021/07/06/heled-rutschman-vertinsky-regulatory-reactivity-fda-approval-aduhelm/.
 |  |
